NEW YORK (GenomeWeb News) — By analyzing the genomes of more than 3,600 strains belonging to a pathogenic group of Streptococcus bacteria, a team of researchers has unraveled the genetic events leading to its emergence as the cause of an epidemic.
NEW YORK (GenomeWeb News) – Meridian Bioscience said on Monday that its illumigene Group A Streptococcus and illumigene Group B Streptococcus assays have been recategorized by the US Food and Drug Administration as "moderate complexity" tests under the Clinical Laboratory Improv
Health management services and diagnostics firm Alere recently updated investors on the progress of a pair of nucleic acid testing platforms that are currently under development at the company and represent the firm's entrée into molecular diagnostics.
Meridian Bioscience said today that its Illumigene molecular diagnostic products accounted for 16 percent of its fiscal first quarter revenues, which increased 13 percent over the same quarter last year.
NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared for marketing Meridian Bioscience's Group A Streptococcus molecular diagnostic test that runs on its illumigene platform, the company said after the close of the market on Monday.